PURPOSE: Fosaprepitant is an antiemetic used for chemotherapy-induced nausea and vomiting. We recently reported increased infusion site adverse events (ISAE) in a cohort of breast cancer patients receiving chemotherapy with doxorubicin and cyclophosphamide (AC). In this current study, we evaluated the venous toxicity of fosaprepitant use with non-anthracycline platinum-based antineoplastic regimens. METHODS: A retrospective review was conducted of the first 81 patients initiated on fosaprepitant among patients receiving highly emetogenic chemotherapy, on or after January 1, 2011 at Mayo Clinic Rochester. None of these regimens included an anthracycline. Data collected included baseline demographics, chemotherapy regimen, type of intravenous access and type, and severity of ISAE. Data from these patients were compared to previously collected data from patients who had received AC. Statistical analysis using χ 2 and univariate logistic regression was used to evaluate the association between treatment regimen, fosaprepitant, and risk of ISAE. RESULTS: Among these 81 patients, the incidence of ISAE was 7.4% in the non-anthracycline platinum group. The most commonly reported ISAE were swelling (3%), extravasation (3%), and phlebitis (3%). When stratified by regimen, fosaprepitant was associated with a statistically significant increased risk of ISAE in the anthracycline group (OR 8.1; 95% CI 2.0-31.9) compared to the platinum group. CONCLUSIONS: Fosaprepitant antiemetic therapy causes significant ISAE that are appreciably higher than previous reports. Patients receiving platinum-based chemotherapy appear to have less significant ISAE than do patients who receive anthracycline-based regimens.
PURPOSE: Fosaprepitant is an antiemetic used for chemotherapy-induced nausea and vomiting. We recently reported increased infusion site adverse events (ISAE) in a cohort of breast cancerpatients receiving chemotherapy with doxorubicin and cyclophosphamide (AC). In this current study, we evaluated the venous toxicity of fosaprepitant use with non-anthracycline platinum-based antineoplastic regimens. METHODS: A retrospective review was conducted of the first 81 patients initiated on fosaprepitant among patients receiving highly emetogenic chemotherapy, on or after January 1, 2011 at Mayo Clinic Rochester. None of these regimens included an anthracycline. Data collected included baseline demographics, chemotherapy regimen, type of intravenous access and type, and severity of ISAE. Data from these patients were compared to previously collected data from patients who had received AC. Statistical analysis using χ 2 and univariate logistic regression was used to evaluate the association between treatment regimen, fosaprepitant, and risk of ISAE. RESULTS: Among these 81 patients, the incidence of ISAE was 7.4% in the non-anthracycline platinum group. The most commonly reported ISAE were swelling (3%), extravasation (3%), and phlebitis (3%). When stratified by regimen, fosaprepitant was associated with a statistically significant increased risk of ISAE in the anthracycline group (OR 8.1; 95% CI 2.0-31.9) compared to the platinum group. CONCLUSIONS: Fosaprepitant antiemetic therapy causes significant ISAE that are appreciably higher than previous reports. Patients receiving platinum-based chemotherapy appear to have less significant ISAE than do patients who receive anthracycline-based regimens.
Authors: F Roila; J Herrstedt; M Aapro; R J Gralla; L H Einhorn; E Ballatori; E Bria; R A Clark-Snow; B T Espersen; P Feyer; S M Grunberg; P J Hesketh; K Jordan; M G Kris; E Maranzano; A Molassiotis; G Morrow; I Olver; B L Rapoport; C Rittenberg; M Saito; M Tonato; D Warr Journal: Ann Oncol Date: 2010-05 Impact factor: 32.976
Authors: Kenneth C Lasseter; Jay Gambale; Bo Jin; Art Bergman; Marvin Constanzer; James Dru; Tae H Han; Anup Majumdar; Judith K Evans; M Gail Murphy Journal: J Clin Pharmacol Date: 2007-05-24 Impact factor: 3.126
Authors: Bernardo L Rapoport; Karin Jordan; Judith A Boice; Arlene Taylor; Carole Brown; James S Hardwick; Alexandra Carides; Timothy Webb; Hans-Joachim Schmoll Journal: Support Care Cancer Date: 2009-07-01 Impact factor: 3.603
Authors: A D Leal; K C Kadakia; S Looker; C Hilger; K Sorgatz; K Anderson; A Jacobson; D Grendahl; D Seisler; T Hobday; Charles L Loprinzi Journal: Support Care Cancer Date: 2014-01-09 Impact factor: 3.603
Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: Lucas Vieira dos Santos; Fabiano Hahn Souza; Andre Tesainer Brunetto; Andre Deeke Sasse; João Paulo da Silveira Nogueira Lima Journal: J Natl Cancer Inst Date: 2012-08-21 Impact factor: 13.506
Authors: Lee Schwartzberg; Rudolph Navari; Rebecca Clark-Snow; Ekaterine Arkania; Irena Radyukova; Kamal Patel; Daniel Voisin; Giada Rizzi; Rita Wickham; Richard J Gralla; Matti Aapro; Eric Roeland Journal: Oncologist Date: 2019-12-04
Authors: Bernardo Rapoport; Daniel Chua; Allen Poma; Sujata Arora; Yan Wang; Luis Enrique Fein Journal: Support Care Cancer Date: 2015-05-05 Impact factor: 3.603
Authors: Lee Schwartzberg; Rudolph Navari; Rebecca Clark-Snow; Ekaterine Arkania; Irena Radyukova; Kamal Patel; Daniel Voisin; Giada Rizzi; Rita Wickham; Richard J Gralla; Matti Aapro; Eric Roeland Journal: Oncologist Date: 2019-12-08